MgShell announces the closing of a €1.14 million investment round to accelerate the development of innovative technologies for the treatment of ocular diseases

Milan, April 22, 2025 – MgShell, an Italian MedTech company specializing in the development of innovative solutions for the treatment of ocular diseases, has announced the closing of a €1.14 million seed round. The funding was led by Capital Cell and key opinion leader Dr. Andrea Giani, with participation from existing investors such as Club degli Investitori, Italian Angels for Biotech, and Bios Line Holding.

The capital raised will enable MgShell to accelerate the development and preclinical validation of its proprietary technology, support product development, strengthen the team, and scale up business development activities. The company remains committed to bringing an innovative solution to market that aims to significantly improve patients’ quality of life.

“This investment marks a crucial milestone for MgShell, confirming the strength of our vision and the value of our technology. Thanks to the support of experienced and strategic investors, we are ready to accelerate our path toward clinical validation and market access. Our goal is to offer innovative and effective solutions for the treatment of ocular diseases, significantly improving patients’ quality of life,” said Marco Ferroni, CEO of MgShell.

Daniel Oliver, Director at Capital Cell, commented: “MgShell perfectly embodies the kind of high-potential startup we aim to support in the early stages. Their approach to ocular drug delivery is bold and technically sound. We’re excited to back them in this pivotal development phase.”

Andrea Giani, investor and retinal specialist, added: “MgShell has the potential to revolutionize retinal health with an innovative technology that could reduce the therapeutic burden for patients, caregivers, and physicians. It’s a pleasure to work with such a highly skilled team led by Marco Ferroni and Francesco De Gaetano.”

Enrico Gianotti, Board Member and Champion of Club degli Investitori, stated: “This second investment round represents a strong vote of confidence in MgShell and will play a key role in helping the company achieve its strategic goal of preclinical validation within the expected timeframe. While we recognize the importance and complexity of the steps still ahead, we firmly believe that the strength, dedication, and expertise of the team will be decisive in bringing the project to a successful outcome.”

Federica Girolami, investor and Champion of Italian Angels for Biotech, commented: “MgShell has the potential to transform the ophthalmology sector. The medical device under development addresses urgent clinical needs and could significantly improve patient outcomes.”

Lucio Rovati, CEO of Rottapharm Biotech, stated: “I decided to reinvest in MgShell following the positive results of the initial studies. Their technology is promising and has the potential to become one of the top solutions in the field of retinal diseases.”

Paolo Tramonti, CEO of Bios Line Holding, said: “I recognized in MgShell the same potential I once saw in Next Sight. Marco and his team stand out for their vision and execution capabilities — that’s why I chose to continue investing in the project.”

Stefano Gallucci, Advisor at Bios Line Holding, concluded: “MgShell stands out for its solid governance and ability to reach strategic goals. We have great confidence in the long-term value of the company.”

Special thanks to our Champion Enrico Gianotti and to Silvano Bernardi, Investment Manager at Club degli Investitori, who oversaw the deal on behalf of our Members.